• Research & Development

  Phase 2 Trial of Levosimendan to Treat PH Linked to Specific Heart Failure Moving Forward

  Posted by Pulmonary Hypertension News Moderator on April 11, 2018 at 8:32 pm

  Plans for a Phase 2 clinical trial of levosimendan, a proposed treatment for pulmonary hypertension associated with heart failure and preserved ejection fraction, will soon be submitted to the U.S. Food and Drug Administration for approval, Tenax Therapeutics announced.

  In a pre-application meeting with company executives, the FDA supported the study’s proposed design and measures that will be used to demonstrate proof-of-concept in people with pulmonary hypertension associated with heart failure and preserved ejection fraction, or PH-HFpEF patients, Tenax said in a press release.

  An Investigational New Drug application will soon be submitted, and the trial is expected to open in the summer.

  Read more about Levosimendan as a treatment for PH here: “Phase 2 Trial of Levosimendan to Treat PH Linked to Specific Heart Failure Moving Forward“

  What are your thoughts on this possible treatment? Join the discussion below.

  Pulmonary Hypertension News Moderator replied 7 years, 10 months ago 1 Member · 0 Replies

  • clinical trials
  • levosimendan
  • treating PH
• 0 Replies

Log In to Reply